Evidence Based Medicine on FHIR Implementation Guide
1.0.0-ballot2 - STU 1 ballot International flag

Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 1.0.0-ballot2 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions

Table of Contents

Page standards status: Informative
.. 0 Table of Contents
... 1 Introduction
... 2 Evidence Profiles
... 3 EvidenceVariable Profiles
... 4 Group Profiles
... 5 Citation Profiles
... 6 ArtifactAssessment Profiles
... 7 Composition Profiles
... 8 Other Profiles
... 9 Profiles
... 10 Extensions
... 11 Terminologies
... 12 Examples
... 13 Downloads
... 14 Artifacts Summary
.... 14.1 AbsenceOfExposureDefinition
.... 14.2 Adaptation
.... 14.3 BaselineMeasureEvidence
.... 14.4 BaselineMeasureReport
.... 14.5 BaselineVariablesList
.... 14.6 BookCitation
.... 14.7 BookPartCitation
.... 14.8 CertaintyOfEvidence
.... 14.9 Classification
.... 14.10 CohortDefinition
.... 14.11 Comment
.... 14.12 ComparativeBaselineMeasureEvidence
.... 14.13 ComparativeEvidence
.... 14.14 ComparativeEvidenceReport
.... 14.15 ComparativeEvidenceReportExpanded
.... 14.16 ComparativeEvidenceReportSubject
.... 14.17 ComparativeEvidenceSynthesisReport
.... 14.18 ComparativeParticipantFlowEvidence
.... 14.19 ComparatorGroup
.... 14.20 ComparatorOnlyEvidence
.... 14.21 Comparison
.... 14.22 CompositeRating
.... 14.23 ConceptualCohortDefinition
.... 14.24 ConceptualComparatorDefinition
.... 14.25 ConceptualExposureDefinition
.... 14.26 DatabaseCitation
.... 14.27 DatabaseEntryCitation
.... 14.28 DatasetCitation
.... 14.29 DateAsRating
.... 14.30 DichotomousIntendedOutcome
.... 14.31 EndpointAnalysisPlan
.... 14.32 EvidenceAssessment
.... 14.33 EvidenceList
.... 14.34 EvidenceReport
.... 14.35 EvidenceReportPackage
.... 14.36 EvidenceReportSubject
.... 14.37 EvidenceSynthesisEvidence
.... 14.38 ExposureGroup
.... 14.39 GroupAssignment
.... 14.40 GroupR6
.... 14.41 Guideline
.... 14.42 InterventionOnlyEvidence
.... 14.43 JournalArticleCitation
.... 14.44 M11Report
.... 14.45 MetaanalysisEligibilityCriteria
.... 14.46 MetaanalysisOutcomeDefinition
.... 14.47 MetaanalysisStudyGroup
.... 14.48 NetEffectContribution
.... 14.49 NetEffectContributionList
.... 14.50 NetEffectContributions
.... 14.51 NetEffectEstimate
.... 14.52 NonComparativeEvidence
.... 14.53 OutcomeDefinition
.... 14.54 OutcomeImportance
.... 14.55 OutcomeList
.... 14.56 OutcomeMeasureReport
.... 14.57 OutcomeVariablesList
.... 14.58 ParticipantFlowEvidence
.... 14.59 ParticipantFlowEvidenceVariable
.... 14.60 ParticipantFlowReasonEvidenceVariable
.... 14.61 ParticipantFlowReport
.... 14.62 ParticipantFlowVariablesList
.... 14.63 PreprintCitation
.... 14.64 Rating
.... 14.65 Recommendation
.... 14.66 RecommendationAction
.... 14.67 RecommendationEligibilityCriteria
.... 14.68 RecommendationJustification
.... 14.69 RecommendationPlan
.... 14.70 RecommendationRating
.... 14.71 ResearchStudyDataDictionary
.... 14.72 ResearchStudySupport
.... 14.73 RiskOfBias
.... 14.74 SearchResults
.... 14.75 SearchStrategy
.... 14.76 SingleStudyEvidence
.... 14.77 SoaPlanDefinition
.... 14.78 SoftwareCitation
.... 14.79 StatisticModel
.... 14.80 StudyDesign
.... 14.81 StudyEligibilityCriteria
.... 14.82 StudyGroup
.... 14.83 StudyRegistryRecord
.... 14.84 SummaryOfFindings
.... 14.85 SummaryOfNetEffect
.... 14.86 SystematicReview
.... 14.87 SystematicReviewEligibilityCriteria
.... 14.88 SystematicReviewExcludedStudies
.... 14.89 SystematicReviewIncludedStudies
.... 14.90 VariableDefinition
.... 14.91 WebPageCitation
.... 14.92 ArtifactAssessmentCompared
.... 14.93 ArtifactAssessmentDateAsRating
.... 14.94 ArtifactPublicationStatus
.... 14.95 CharacteristicTiming
.... 14.96 CiteAs
.... 14.97 EvidenceVariableHandlingDetail
.... 14.98 GuidelineRegistration
.... 14.99 NumberAnalyzed
.... 14.100 RelatesTo
.... 14.101 RelatesToClassifier
.... 14.102 RelatesToWithQuotation
.... 14.103 RelativeOutcomeImportance
.... 14.104 ResearchStudyExcludedStudy
.... 14.105 ResearchStudyIncludedStudy
.... 14.106 ResearchStudyIsLowInterventionTrial
.... 14.107 ResearchStudyIsRareDisease
.... 14.108 ResearchStudyNumberOfStudiesIdentified
.... 14.109 ResearchStudyNumberOfStudiesIncluded
.... 14.110 ResearchStudySaeReportingMethod
.... 14.111 ResearchStudySearchStrategy
.... 14.112 ResearchStudySponsorConfidentialityStatement
.... 14.113 ResearchStudyStudyAmendment
.... 14.114 ResearchStudySystematicReviewEligibilityCriteria
.... 14.115 StatisticModelExpression
.... 14.116 StatisticModelIncludeIf
.... 14.117 Desirability Codes Value Set
.... 14.118 EBMonFHIR Profile Name Value Set
.... 14.119 Evidence Rating System Classifier Codes Value Set
.... 14.120 Recommendation Justification Classifier Codes Value Set
.... 14.121 Research Study Document Types Value Set
.... 14.122 Search Strategy Characteristic Value Set
.... 14.123 Desirability Code System
.... 14.124 EBMonFHIR Profile Name Code System
.... 14.125 Evidence Rating System Classifier Code System
.... 14.126 Research Study Document Types Code System
.... 14.127 Search Strategy Characteristic Code System
.... 14.128 11232013 Rosiglitazone monotherapy is effective in patients with type 2 diabetes.
.... 14.129 14-day mortality remdesivir vs placebo meta-analysis (ACTT-1, Wang et al, WHO SOLIDARITY)
.... 14.130 14706014 Chemohormonal therapy as primary treatment for metastatic prostate cancer: a randomized study of estramustine phosphate plus luteinizing hormone-releasing hormone agonist versus flutamide plus luteinizing hormone-releasing hormone agonist.
.... 14.131 15832493 Spotlight on rosiglitazone in the management of type 2 diabetes mellitus.
.... 14.132 15855602 Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia.
.... 14.133 179899
.... 14.134 18160893 Wonder woman. Like my childhood heroine, Mrs. Betty also had amazing powers.
.... 14.135 18508207 A Phase 3 placebo-controlled, double-blind, multi-site trial of the alpha-2-adrenergic agonist, lofexidine, for opioid withdrawal.
.... 14.136 19029421 Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer.
.... 14.137 19091394 Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial.
.... 14.138 19967827 Wonder woman was Argentine and her real name was Evita.
.... 14.139 22056152 Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial.
.... 14.140 22502942 Addition of radiotherapy to long-term androgen deprivation in locally advanced prostate cancer: an open randomised phase 3 trial.
.... 14.141 23306100 Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial.
.... 14.142 23452809 Long-term follow-up of a phase II trial of chemotherapy plus hormone therapy for biochemical relapse after definitive local therapy for prostate cancer.
.... 14.143 23589542 Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society.
.... 14.144 23604530 A phase II trial of androgen deprivation therapy (ADT) plus chemotherapy as initial treatment for local failures or advanced prostate cancer.
.... 14.145 24598155 Long-term results of a phase II study with neoadjuvant docetaxel chemotherapy and complete androgen blockade in locally advanced and high-risk prostate cancer.
.... 14.146 25301760 Survival with Newly Diagnosed Metastatic Prostate Cancer in the "Docetaxel Era": Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019).
.... 14.147 26002607 Should docetaxel be standard of care for patients with metastatic hormone-sensitive prostate cancer? Pro and contra.
.... 14.148 26028518 Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial.
.... 14.149 26092557 Feasibility study of a randomized controlled trial comparing docetaxel chemotherapy and androgen deprivation therapy with sequential prostatic biopsies from patients with advanced non-castration-resistant prostate cancer.
.... 14.150 26244877 Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer.
.... 14.151 26502880 A novel nasal powder formulation of glucagon: toxicology studies in animal models.
.... 14.152 26681725 Intranasal Glucagon for Treatment of Insulin-Induced Hypoglycemia in Adults With Type 1 Diabetes: A Randomized Crossover Noninferiority Study.
.... 14.153 26859072 Emotional Distress in the Partners of Type 1 Diabetes Adults: Worries About Hypoglycemia and Other Key Concerns.
.... 14.154 27222544 Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: A Joint Statement by International Diabetes Organizations.
.... 14.155 27308831 Efficacy and Safety of Combined Androgen Deprivation Therapy (ADT) and Docetaxel Compared with ADT Alone for Metastatic Hormone-Naive Prostate Cancer: A Systematic Review and Meta-Analysis.
.... 14.156 27979893 6. Glycemic Targets.
.... 14.157 29114761 Web Exclusives. Annals Story Slam - How Wonder Woman Became My Alter Ego.
.... 14.158 29114762 Web Exclusives. Annals Story Slam - Wonder Woman Is a Cartoon Character.
.... 14.159 29202628 "I Kinda Feel Like Wonder Woman": An Interpretative Phenomenological Analysis of Pole Fitness and Positive Body Image.
.... 14.160 29357271 Using Hawkeye from the Avengers to communicate on the eye.
.... 14.161 29694275 A regressive formula of perversity: Wertham and the women of comics.
.... 14.162 29694302 Introduction: "Suffering Sappho!": Lesbian content and queer female characters in comics.
.... 14.163 30467172 Finding my inner Wonder Woman.
.... 14.164 30545967 Parachute use to prevent death and major trauma when jumping from aircraft: randomized controlled trial.
.... 14.165 34871555 What Can Wonder Woman Teach Radiologists?
.... 14.166 35243488 Bariatric surgery and cardiovascular disease: a systematic review and meta-analysis.
.... 14.167 36491989 Another Georgia Wonder Woman: She Does More Astounding Tricks Than Did Lula Hurst.
.... 14.168 367832
.... 14.169 367833
.... 14.170 37024129 Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials.
.... 14.171 38584159 Efficacy and safety of a four-drug, quarter-dose treatment for hypertension: the QUARTET USA randomized trial.
.... 14.172 6907780 Career guide: to change what needs changing...doesn't take Wonder Woman.
.... 14.173 A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus
.... 14.174 A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus - M11 Example
.... 14.175 ADAS-Cog(11) EndpointAnalysisPlan from PHUSE Lilly Redacted Protocol - EBMonFHIR IG Version
.... 14.176 Add-on Amlodipine at 6 weeks
.... 14.177 Adults with diabetes mellitus type 2
.... 14.178 Adults with type 2 diabetes and CVD and CKD
.... 14.179 Adults with type 2 diabetes and established CVD (but no CKD)
.... 14.180 Adverse event free and hypertension control
.... 14.181 Adverse event free and hypertension control at 12 weeks
.... 14.182 Adverse Events Report for NCT03640312
.... 14.183 Age
.... 14.184 Age with comparator
.... 14.185 Age with intervention
.... 14.186 Aircraft Type
.... 14.187 Aircraft Type with comparator
.... 14.188 Aircraft Type with intervention
.... 14.189 Altitude
.... 14.190 Altitude comparing intervention vs. comparator
.... 14.191 Altitude for enrolled group
.... 14.192 Altitude for screened group
.... 14.193 Altitude with comparator
.... 14.194 Altitude with intervention
.... 14.195 Analyzed Group in PARACHUTE Trial
.... 14.196 Anticoagulation for COVID-19 Combined RCTs in NEJM
.... 14.197 Baseline Characteristics Report for NCT03640312
.... 14.198 Baseline Characteristics Report for QUARTET Trial
.... 14.199 Baseline Measure Report: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)
.... 14.200 Baseline Measures List for PARACHUTE Trial
.... 14.201 BaselineMeasureEvidence: Age in 2018 Norwegian Cohort Medical Group
.... 14.202 BaselineMeasureEvidence: Age in 2018 Norwegian Cohort Surgical Group
.... 14.203 BaselineMeasureEvidence: BMI in 2018 Norwegian Cohort Medical Group
.... 14.204 BaselineMeasureEvidence: BMI in 2018 Norwegian Cohort Surgical Group
.... 14.205 BaselineVariablesList: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)
.... 14.206 Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials
.... 14.207 BookCitation: Crossing the Quality Chasm: A New Health System for the 21st Century
.... 14.208 BookPartCitation: Chapter 3 of Crossing the Quality Chasm: A New Health System for the 21st Century
.... 14.209 BookPartCitation: Chapter 3 of Crossing the Quality Chasm: A New Health System for the 21st Century - without baseCitation
.... 14.210 Candesartan 8 mg once daily
.... 14.211 Certainty of Evidence Rating of 14-day mortality remdesivir vs placebo meta-analysis (ACTT-1, Wang et al, WHO SOLIDARITY)
.... 14.212 Change in Mean Diastolic Blood Pressure (NCT03640312)
.... 14.213 Change in Mean Diastolic Blood Pressure at 6 weeks for Candesartan in NCT03640312
.... 14.214 Change in Mean Diastolic Blood Pressure at 6 weeks for QUARTET LDQT in NCT03640312
.... 14.215 Change in Mean Diastolic Blood Pressure at 6 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 14.216 Change in Mean Systolic Blood Pressure (NCT03640312)
.... 14.217 Change in Mean Systolic Blood Pressure (NCT03640312)
.... 14.218 Change in Mean Systolic Blood Pressure at 12 weeks for Candesartan in NCT03640312
.... 14.219 Change in Mean Systolic Blood Pressure at 12 weeks for QUARTET LDQT in NCT03640312
.... 14.220 Change in Mean Systolic Blood Pressure at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 14.221 Change in Mean Systolic Blood Pressure at 6 weeks for Candesartan in NCT03640312
.... 14.222 Change in Mean Systolic Blood Pressure at 6 weeks for QUARTET LDQT in NCT03640312
.... 14.223 Change in Mean Systolic Blood Pressure at 6 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 14.224 CIBIC+ EndpointAnalysisPlan from PHUSE Lilly Redacted Protocol - EBMonFHIR IG Version
.... 14.225 Citation for Composition: ComparativeEvidenceReport: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)
.... 14.226 Citation for EBMonFHIR Implementation Guide
.... 14.227 Citation for FEvIR Evidence 55: 14-day mortality remdesivir vs placebo meta-analysis (ACTT-1, Wang et al, WHO SOLIDARITY)
.... 14.228 Citation for FEvIR Evidence 7637: Critically appraised summary of primary outcome of multi-platform RCT of anticoagulation for non-critically ill COVID-19
.... 14.229 Classification: Study Design for Association of Bariatric Surgery with Complications and Comorbidities JAMA 2018 Norwegian Cohort
.... 14.230 Comment on Guideline: ADA 2021 Standards of Medical Care 8. Obesity Management for the Treatment of Type 2 Diabetes by Joanne Dehnbostel 2023-11-28T15:19:01.266Z
.... 14.231 Comparative Evidence Report for QUARTET USA Trial
.... 14.232 ComparativeBaselineMeasureEvidence: Age in 2018 Norwegian Cohort Surgical Group vs. Medical Group
.... 14.233 ComparativeBaselineMeasureEvidence: BMI in 2018 Norwegian Cohort Surgical Group vs. Medical Group
.... 14.234 ComparativeEvidence: All-cause mortality effect of bariatric surgery in 2022 meta-analysis
.... 14.235 ComparativeEvidence: Bariatric Surgery effect for ADA triple outcome at 5 years (Diabetes Surgery Study)
.... 14.236 ComparativeEvidence: Bypass surgery effects on Additional GI surgical procedure in JAMA 2018 Norwegian cohort study
.... 14.237 ComparativeEvidence: Bypass surgery effects on Myocardial infarction or stroke in Swedish Obese Subjects (SOS) study
.... 14.238 ComparativeEvidence: Bypass surgery effects on New onset depression in JAMA 2018 Norwegian cohort study
.... 14.239 ComparativeEvidence: Bypass surgery effects on Remission of diabetes in JAMA 2018 Norwegian cohort study
.... 14.240 ComparativeEvidence: Bypass surgery effects on Treatment with opioids in JAMA 2018 Norwegian cohort study
.... 14.241 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Courcoulas 2014
.... 14.242 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Courcoulas 2015
.... 14.243 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Cummings 2016
.... 14.244 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Ding 2015
.... 14.245 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Dixon 2008
.... 14.246 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Halperin 2014
.... 14.247 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Ikramuddin 2013
.... 14.248 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Ikramuddin 2015
.... 14.249 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Liang 2013
.... 14.250 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Mingrone 2012 (DIBASY) trial
.... 14.251 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Mingrone 2015 (DIBASY) trial
.... 14.252 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Parikh 2014
.... 14.253 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Schauer 2012 (STAMPEDE) trial
.... 14.254 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Schauer 2014 (STAMPEDE) trial
.... 14.255 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Wentworth 2014
.... 14.256 ComparativeEvidence: Mean difference in HbA1c effect of bariatric surgery in 2016 meta-analysis
.... 14.257 ComparativeEvidenceReport: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)
.... 14.258 ComparativeEvidenceReportSubject: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)
.... 14.259 ComparativeEvidenceSynthesisReport: GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 14.260 ComparativeParticipantFlowEvidence: Dropout due to stopping intervention Lofexidine vs. Placebo in opioid detoxification trial
.... 14.261 ComparatorDefinition: Glucagon-Like Peptide-1 (GLP-1) receptor agonists
.... 14.262 ComparatorDefinition: Obese patients ≥ 18 years old without bariatric surgery
.... 14.263 ComparatorDefinition: Standard care
.... 14.264 ComparatorGroup: JAMA 2018 Norwegian cohort study Control cohort
.... 14.265 ComparatorOnlyEvidence: Additional GI surgical procedure without bariatric surgery (Control Group) in JAMA 2018 Norwegian cohort study
.... 14.266 ComparatorOnlyEvidence: All-cause mortality without bariatric surgery in 2022 meta-analysis
.... 14.267 ComparatorOnlyEvidence: Myocardial infarction or stroke without bariatric surgery (Control Group) in Swedish Obese Subjects (SOS) study
.... 14.268 ComparatorOnlyEvidence: New onset depression without bariatric surgery (Control Group) in JAMA 2018 Norwegian cohort study
.... 14.269 ComparatorOnlyEvidence: Remission of diabetes without bariatric surgery (Control Group) in JAMA 2018 Norwegian cohort study
.... 14.270 ComparatorOnlyEvidence: Treatment with opioids without bariatric surgery (Control Group) in JAMA 2018 Norwegian cohort study
.... 14.271 Comparison: Original and Adapted Recommendation: ADA Obesity Management Recommendation 8.16
.... 14.272 Composite Rating of FOI 153881 for Project FOI 112280
.... 14.273 Computable_Publishing_LLC
.... 14.274 ConceptualCohortDefinition: At least 2 risk factors for stroke
.... 14.275 ConceptualCohortDefinition: BMI 27.5-32.4 in Asian Americans who do not achieve durable weight loss and improvement in comorbidities without surgery
.... 14.276 ConceptualCohortDefinition: BMI 30-34.9 in persons who do not achieve durable weight loss and improvement in comorbidities without surgery
.... 14.277 ConceptualCohortDefinition: BMI 32.5-37.4 in Asian Americans who do not achieve durable weight loss and improvement in comorbidities without surgery
.... 14.278 ConceptualCohortDefinition: BMI 35-39.9 in persons who do not achieve durable weight loss and improvement in comorbidities without surgery
.... 14.279 ConceptualCohortDefinition: BMI criteria for ADA surgery recommendation
.... 14.280 ConceptualCohortDefinition: BMI ≥ 35 and at least 1 obesity-related comorbidity
.... 14.281 ConceptualCohortDefinition: BMI ≥ 37.5 kg/m2 in Asian Americans
.... 14.282 ConceptualCohortDefinition: Estimated glomerular filtration rate 45-59
.... 14.283 ConceptualCohortDefinition: Heart failure based on Phenotypes
.... 14.284 ConceptualCohortDefinition: Lower BMI criteria for ADA surgery consideration
.... 14.285 ConceptualCohortDefinition: Meet either T1DM-specific eligibility criteria or T2DM-specific eligibility criteria
.... 14.286 ConceptualCohortDefinition: Nonfatal myocardial infarction
.... 14.287 ConceptualCohortDefinition: Nonfatal stroke
.... 14.288 ConceptualCohortDefinition: Oxygen saturation < 96% on Boots Finger Pulse Oximeter
.... 14.289 ConceptualCohortDefinition: Oxygen saturation < 96% on Boots Finger Pulse Oximeter with Ranges
.... 14.290 ConceptualCohortDefinition: Proxy criteria for surgical candidates
.... 14.291 ConceptualCohortDefinition: Severe obesity
.... 14.292 ConceptualCohortDefinition: T1DM or T2DM
.... 14.293 ConceptualCohortDefinition: T1DM-specific criteria
.... 14.294 ConceptualCohortDefinition: T2DM-specific criteria
.... 14.295 ConceptualCohortDefinition_Cancer_of_any_kind_except_basal_cell_skin_cancer_or_cancer_in_situ_unless_documented_to_be_disease_free_for_five_years
.... 14.296 ConceptualCohortDefinition_Cardiovascular_event
.... 14.297 ConceptualComparatorDefinition: NOT Bariatric Surgery (RYGB, VSG, LAGB, BPD)
.... 14.298 ConceptualComparatorDefinition: Usual-care pharmacologic thromboprophylaxis
.... 14.299 ConceptualExposureDefinition: Bariatric Surgery (RYGB, VSG, LAGB, BPD)
.... 14.300 ConceptualExposureDefinition: Therapeutic-dose anticoagulation with heparin
.... 14.301 COVID_19PneumoniaHospitalizedAdult
.... 14.302 Critically appraised summary of primary outcome of multi-platform RCT of anticoagulation for non-critically ill patients with COVID-19
.... 14.303 CTIS2024-516402-32-00 Eligibility Criteria
.... 14.304 CTIS2024-516402-32-00 Primary Outcome 1
.... 14.305 CTIS2024-516402-32-00 Secondary Outcome 1
.... 14.306 CTIS2024-516402-32-00 Secondary Outcome 2
.... 14.307 CTIS2024-516402-32-00 Secondary Outcome 3
.... 14.308 CTIS2024-516402-32-00 Secondary Outcome 4
.... 14.309 CTIS2024-516402-32-00 Secondary Outcome 5
.... 14.310 CTIS2024-516402-32-00 Secondary Outcome 6
.... 14.311 CTIS2024-516402-32-00 Secondary Outcome 7
.... 14.312 CTIS2024-516402-32-00 Secondary Outcome 8
.... 14.313 DatabaseCitation: Citation for FEvIR Platform
.... 14.314 DatabaseEntryCitation: ComparativeEvidenceReport: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)
.... 14.315 DatasetCitation: Extrachromosomal DNA Amplification Contributes to Small Cell Lung Cancer Heterogeneity and is Associated with Worse Outcomes
.... 14.316 DateOfFirstPublication Classification of FOI 153881 by Rachel Couban
.... 14.317 Death or Major Traumatic Injury 30 days after Impact comparing intervention vs. comparator
.... 14.318 Death or Major Traumatic Injury 30 days after Impact with comparator
.... 14.319 Death or Major Traumatic Injury 30 days after Impact with intervention
.... 14.320 Death or Major Traumatic Injury on Impact comparing intervention vs. comparator
.... 14.321 declined randomization in PARACHUTE Study
.... 14.322 deemed unsuitable by investigator in PARACHUTE Trial
.... 14.323 Delany-Moretlwe 2022 clinical trial
.... 14.324 Diabetes treatment medication
.... 14.325 Diastolic blood pressure at 12 weeks
.... 14.326 DichotomousIntendedOutcome: Death or Major Traumatic Injury within 30 days
.... 14.327 Eculizumab in hypertensive emergency-associated hemolytic uremic syndrome: a randomized multicenter controlled trial (HYPERSHU)
.... 14.328 Efficacy and Safety of a Quadruple Ultra-low-dose Treatment for Hypertension
.... 14.329 Efficacy of Corticosteroids in COVID-19 Patients: A Systematic Review and Meta-Analysis
.... 14.330 Eligibility criteria for NMA_Diabetes
.... 14.331 Eligibility Criteria for QUARTET USA Trial
.... 14.332 Enrolled Group for QUARTET USA Trial
.... 14.333 Enrolled Group PARACHUTE Trial
.... 14.334 Epidemiologie, Diagnostik und Therapie erwachsener Patienten mit nosokomialer Pneumonie
.... 14.335 Ethnic Group
.... 14.336 Ethnic Group with comparator
.... 14.337 Ethnic Group with intervention
.... 14.338 Evidence Based Medicine on FHIR Implementation Guide Code System
.... 14.339 Evidence for Results for Add-on Amlodipine at 6 weeks in GroupAssignment: Quadpill vs. Candesartan
.... 14.340 Evidence for Results for Add-on Amlodipine at 6 weeks in GroupAssignment: Quadpill vs. Candesartan
.... 14.341 Evidence for Results for Add-on Amlodipine at 6 weeks in QUARTET USA Trial Control Group
.... 14.342 Evidence for Results for Add-on Amlodipine at 6 weeks in QUARTET USA Trial Quadpill group
.... 14.343 Evidence for Results for Adverse event free and hypertension control at 12 weeks in GroupAssignment: Quadpill vs. Candesartan
.... 14.344 Evidence for Results for Adverse event free and hypertension control at 12 weeks in GroupAssignment: Quadpill vs. Candesartan
.... 14.345 Evidence for Results for Adverse event free and hypertension control at 12 weeks in QUARTET USA Trial Control Group
.... 14.346 Evidence for Results for Adverse event free and hypertension control at 12 weeks in QUARTET USA Trial Quadpill group
.... 14.347 Evidence for Results for Diastolic blood pressure at 12 weeks in GroupAssignment: Quadpill vs. Candesartan
.... 14.348 Evidence for Results for Diastolic blood pressure at 12 weeks in GroupAssignment: Quadpill vs. Candesartan
.... 14.349 Evidence for Results for Diastolic blood pressure at 12 weeks in QUARTET USA Trial Control Group
.... 14.350 Evidence for Results for Diastolic blood pressure at 12 weeks in QUARTET USA Trial Quadpill group
.... 14.351 Evidence for Results for Hypertension Control at 12 weeks in GroupAssignment: Quadpill vs. Candesartan
.... 14.352 Evidence for Results for Hypertension Control at 12 weeks in GroupAssignment: Quadpill vs. Candesartan
.... 14.353 Evidence for Results for Hypertension Control at 12 weeks in QUARTET USA Trial Control Group
.... 14.354 Evidence for Results for Hypertension Control at 12 weeks in QUARTET USA Trial Quadpill group
.... 14.355 Evidence for Results for Medication Adherence at 12 weeks in GroupAssignment: Quadpill vs. Candesartan
.... 14.356 Evidence for Results for Medication Adherence at 12 weeks in GroupAssignment: Quadpill vs. Candesartan
.... 14.357 Evidence for Results for Medication Adherence at 12 weeks in QUARTET USA Trial Control Group
.... 14.358 Evidence for Results for Medication Adherence at 12 weeks in QUARTET USA Trial Quadpill group
.... 14.359 Evidence for Results for Systolic blood pressure at 12 weeks in GroupAssignment: Quadpill vs. Candesartan
.... 14.360 Evidence for Results for Systolic blood pressure at 12 weeks in GroupAssignment: Quadpill vs. Candesartan
.... 14.361 Evidence for Results for Systolic blood pressure at 12 weeks in QUARTET USA Trial Control Group
.... 14.362 Evidence for Results for Systolic blood pressure at 12 weeks in QUARTET USA Trial Quadpill group
.... 14.363 Evidence List: Effect estimates for meta-analysis (Biegel 2020, Wang 2020, SOLIDARITY)
.... 14.364 EvidenceList: Study results included in Mean difference in HbA1c effect of bariatric surgery in 2016 meta-analysis
.... 14.365 EvidenceReportSectionCode Value Set
.... 14.366 EvidenceReportSubject: Clinical Outcomes for Effects of Bariatric Surgery
.... 14.367 EvidenceVariable Handling Extension Value Set
.... 14.368 EvidenceVariable: case_id
.... 14.369 EvidenceVariable: Patient id
.... 14.370 EvidenceVariable: Time of measurement
.... 14.371 Example EndpointAnalysisPlan from PHUSE Lilly Redacted Protocol - EBMonFHIR IG Version
.... 14.372 Excluded from PARACHUTE Study
.... 14.373 ExposureGroup: JAMA 2018 Norwegian cohort study Surgery cohort
.... 14.374 ExposureVariable: Age (as continuous variable)
.... 14.375 ExposureVariable: Body Mass Index (as continuous variable)
.... 14.376 ExposureVariable: pht013093.v1.p1 Age at diagnosis
.... 14.377 ExposureVariable: pht013093.v1.p1 RACE
.... 14.378 ExposureVariable: pht013093.v1.p1 SEX
.... 14.379 ExposureVariable: pht013093.v1.p1 SUBJECT_ID
.... 14.380 ExposureVariable: pht013094.v1.p1 ANALYTE_TYPE
.... 14.381 ExposureVariable: pht013094.v1.p1 BODY_SITE
.... 14.382 ExposureVariable: pht013094.v1.p1 IS_TUMOR
.... 14.383 ExposureVariable: pht013094.v1.p1 SAMPLE_ID
.... 14.384 ExposureVariable: pht013094.v1.p1 SAMPLE_USE
.... 14.385 ExposureVariable: pht013094.v1.p1 Source_Type
.... 14.386 Family History of Parachute Use
.... 14.387 Family History of Parachute Use with comparator
.... 14.388 Family History of Parachute Use with intervention
.... 14.389 Frequent Flier
.... 14.390 Frequent Flier with comparator
.... 14.391 Frequent Flier with intervention
.... 14.392 GLP-1 RA Group in Adults with type 2 diabetes
.... 14.393 GLP-1 RA Group in at-risk Adults with type 2 diabetes with moderate CV risk
.... 14.394 Glucagon Hydrochloride Solution (Active Comparator)
.... 14.395 Glucagon Nasal Powder (Experimental)
.... 14.396 Group Randomized to Comparator (empty backpack) in PARACHUTE Trial
.... 14.397 Group Randomized to Intervention Group (parachute) in PARACHUTE Trial
.... 14.398 GroupAssignment: Bariatric Surgery vs. no bariatric surgery
.... 14.399 GroupAssignment: ExposureDefinition: Bariatric Surgery (RYGB, VSG, LAGB, BPD) vs. ComparatorDefinition: NOT Bariatric Surgery (RYGB, VSG, LAGB, BPD)
.... 14.400 GroupAssignment: ExposureGroup: JAMA 2018 Norwegian cohort study Surgery cohort vs. ComparatorGroup: JAMA 2018 Norwegian cohort study Control cohort
.... 14.401 GroupAssignment: GLP-1 RA vs. Standard care
.... 14.402 GroupAssignment: high dose xanomeline vs. low dose xanomeline vs. placebo
.... 14.403 GroupAssignment: Jumping from aircraft with parachute vs. Jumping from aircraft with empty backpack
.... 14.404 GroupAssignment: Non Participants vs. Enrolled Participants
.... 14.405 GroupAssignment: Quadpill vs. Candesartan
.... 14.406 GroupAssignment: Roux-en-Y gastric bypass or Biliopancreatic Diversion vs. medical treatment
.... 14.407 GroupAssignment: Roux-en-Y gastric bypass surgery vs. Lifestyle-intensive medical management intervention alone
.... 14.408 GroupAssignment: Roux-en-Y gastric bypass vs. medical treatment
.... 14.409 GroupAssignment: SGLT2 inhibitors vs. GLP-1 RA
.... 14.410 GroupAssignment: Therapeutic-dose anticoagulation with heparin vs. Usual-care pharmacologic thromboprophylaxis
.... 14.411 Guideline: ADA 2021 Standards of Medical Care 8. Obesity Management for the Treatment of Type 2 Diabetes
.... 14.412 Health Survey Score Total
.... 14.413 Health Survey Score Total comparing intervention vs. comparator
.... 14.414 Health Survey Score Total with comparator
.... 14.415 Health Survey Score Total with intervention
.... 14.416 Health Survey Score-Mental Health Subscore
.... 14.417 Health Survey Score-Mental Health Subscore comparing intervention vs. comparator
.... 14.418 Health Survey Score-Mental Health Subscore with comparator
.... 14.419 Health Survey Score-Mental Health Subscore with intervention
.... 14.420 Health Survey Score-Physical Health Subscore
.... 14.421 Health Survey Score-Physical Health Subscore comparing intervention vs. comparator
.... 14.422 Health Survey Score-Physical Health Subscore with comparator
.... 14.423 Health Survey Score-Physical Health Subscore with intervention
.... 14.424 Health-related Quality of Life (NCT03640312)
.... 14.425 Health-related Quality of Life at 12 weeks - Change in Mental Health T score (PROMIS) at (NCT03640312)
.... 14.426 Health-related Quality of Life at 12 weeks - Change in Mental Health T score (PROMIS) for Candesartan in NCT03640312
.... 14.427 Health-related Quality of Life at 12 weeks - Change in Mental Health T score (PROMIS) for QUARTET LDQT in NCT03640312
.... 14.428 Health-related Quality of Life at 12 weeks - Change in Physical Health T score (PROMIS) at (NCT03640312)
.... 14.429 Health-related Quality of Life at 12 weeks - Change in Physical Health T score (PROMIS) for Candesartan in NCT03640312
.... 14.430 Health-related Quality of Life at 12 weeks - Change in Physical Health T score (PROMIS) for QUARTET LDQT in NCT03640312
.... 14.431 Health-related Quality of Life at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 14.432 Health-related Quality of Life at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 14.433 Height
.... 14.434 Height with comparator
.... 14.435 Height with intervention
.... 14.436 High Blood Pressure Medication Value Set
.... 14.437 History of Acrophobia
.... 14.438 History of Acrophobia with comparator
.... 14.439 History of Acrophobia with intervention
.... 14.440 History of Broken Bones
.... 14.441 History of Broken Bones with comparator
.... 14.442 History of Broken Bones with intervention
.... 14.443 History of Parachute Use
.... 14.444 History of Parachute Use with comparator
.... 14.445 History of Parachute Use with intervention
.... 14.446 Hypertension Control at 12 weeks
.... 14.447 ICD-10-GM Terminale Codes
.... 14.448 Injury Severity Score 30 days after Impact comparing intervention vs. comparator
.... 14.449 Injury Severity Score 30 days after Impact with comparator
.... 14.450 Injury Severity Score 30 days after Impact with intervention
.... 14.451 Injury Severity Score on Impact comparing intervention vs. comparator
.... 14.452 Injury Severity Score on Impact with comparator
.... 14.453 Injury Severity Score on Impact with intervention
.... 14.454 International vs Domestic Flight
.... 14.455 International vs Domestic Flight with comparator
.... 14.456 International vs Domestic Flight with intervention
.... 14.457 InterventionDefinition: Glucagon-Like Peptide-1 (GLP-1) receptor agonists
.... 14.458 InterventionDefinition: Sodium-Glucose Transport Protein 2 (SGLT2) inhibitors
.... 14.459 InterventionOnlyEvidence: Additional GI surgical procedure with bariatric surgery (Intervention Group) in JAMA 2018 Norwegian cohort study
.... 14.460 InterventionOnlyEvidence: New onset depression with bariatric surgery (Intervention Group) in JAMA 2018 Norwegian cohort study
.... 14.461 InterventionOnlyEvidence: Remission of diabetes with bariatric surgery (Intervention Group) in JAMA 2018 Norwegian cohort study
.... 14.462 InterventionOnlyEvidence: Treatment with opioids with bariatric surgery (Intervention Group) in JAMA 2018 Norwegian cohort study
.... 14.463 Investigator
.... 14.464 Investigator-by-treatment interaction for ADAS-Cog(11) ANCOVA
.... 14.465 IV remdesivir 200 mg then 100 mg/day for 9 days
.... 14.466 Joanne Dehnbostel's Adaptation Report of Recommendation: ADA Obesity Management Recommendation 8.16
.... 14.467 JournalArticleCitation: ADA 2021 Standards of Medical Care 8. Obesity Management for the Treatment of Type 2 Diabetes
.... 14.468 JournalArticleCitation: Association of Bariatric Surgery with Complications and Comorbidities JAMA 2018 Norwegian Cohort
.... 14.469 Jumping from aircraft with empty backpack
.... 14.470 Jumping from aircraft with parachute
.... 14.471 Justification for Recommendation: ADA Obesity Management Recommendation 8.16
.... 14.472 Justification for Recommendation: ADA Obesity Management Recommendation 8.17
.... 14.473 M11 IGBJ Protocol Example Eligibility Criteria
.... 14.474 M11 IGBJ Protocol Example for EBMonFHIR IG
.... 14.475 M11 Report Template Instructions
.... 14.476 MAGIC-derived ComparatorOnlyEvidence: All-cause mortality in GLP-1 RA Group in Adults with type 2 diabetes
.... 14.477 MAGIC-derived ComparatorOnlyEvidence: All-cause mortality in Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 14.478 MAGIC-derived ComparatorOnlyEvidence: Body weight in GLP-1 RA Group in Adults with type 2 diabetes
.... 14.479 MAGIC-derived ComparatorOnlyEvidence: Body weight in Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 14.480 MAGIC-derived ComparatorOnlyEvidence: Cardiovascular mortality in GLP-1 RA Group in Adults with type 2 diabetes
.... 14.481 MAGIC-derived ComparatorOnlyEvidence: Cardiovascular mortality in Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 14.482 MAGIC-derived ComparatorOnlyEvidence: Diabetic ketoacidosis in GLP-1 RA Group in Adults with type 2 diabetes
.... 14.483 MAGIC-derived ComparatorOnlyEvidence: End-stage kidney disease in GLP-1 RA Group in Adults with type 2 diabetes
.... 14.484 MAGIC-derived ComparatorOnlyEvidence: End-stage kidney disease in Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 14.485 MAGIC-derived ComparatorOnlyEvidence: Genital infection in GLP-1 RA Group in Adults with type 2 diabetes
.... 14.486 MAGIC-derived ComparatorOnlyEvidence: Health-related quality of life in GLP-1 RA Group in Adults with type 2 diabetes
.... 14.487 MAGIC-derived ComparatorOnlyEvidence: Health-related quality of life in Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 14.488 MAGIC-derived ComparatorOnlyEvidence: Heart failure in GLP-1 RA Group in Adults with type 2 diabetes
.... 14.489 MAGIC-derived ComparatorOnlyEvidence: Heart failure in Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 14.490 MAGIC-derived ComparatorOnlyEvidence: Nonfatal myocardial infarction in GLP-1 RA Group in Adults with type 2 diabetes
.... 14.491 MAGIC-derived ComparatorOnlyEvidence: Nonfatal myocardial infarction in Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 14.492 MAGIC-derived ComparatorOnlyEvidence: Nonfatal stroke in GLP-1 RA Group in Adults with type 2 diabetes
.... 14.493 MAGIC-derived ComparatorOnlyEvidence: Nonfatal stroke in Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 14.494 MAGIC-derived ComparatorOnlyEvidence: Serious hyperglycaemia in GLP-1 RA Group in Adults with type 2 diabetes
.... 14.495 MAGIC-derived ComparatorOnlyEvidence: Serious hyperglycaemia in Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 14.496 MAGIC-derived ComparatorOnlyEvidence: Severe gastrointestinal events in GLP-1 RA Group in Adults with type 2 diabetes
.... 14.497 MAGIC-derived ComparatorOnlyEvidence: Severe gastrointestinal events in Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 14.498 MAGIC-derived Evidence: All-cause mortality with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 14.499 MAGIC-derived Evidence: All-cause mortality with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 14.500 MAGIC-derived Evidence: Body weight with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 14.501 MAGIC-derived Evidence: Body weight with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 14.502 MAGIC-derived Evidence: Cardiovascular mortality with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 14.503 MAGIC-derived Evidence: Cardiovascular mortality with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 14.504 MAGIC-derived Evidence: Diabetic ketoacidosis with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 14.505 MAGIC-derived Evidence: End-stage kidney disease with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 14.506 MAGIC-derived Evidence: End-stage kidney disease with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 14.507 MAGIC-derived Evidence: Genital infection with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 14.508 MAGIC-derived Evidence: Health-related quality of life with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 14.509 MAGIC-derived Evidence: Health-related quality of life with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 14.510 MAGIC-derived Evidence: Heart failure with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 14.511 MAGIC-derived Evidence: Heart failure with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 14.512 MAGIC-derived Evidence: Nonfatal myocardial infarction with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 14.513 MAGIC-derived Evidence: Nonfatal myocardial infarction with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 14.514 MAGIC-derived Evidence: Nonfatal stroke with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 14.515 MAGIC-derived Evidence: Nonfatal stroke with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 14.516 MAGIC-derived Evidence: Serious hyperglycaemia with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 14.517 MAGIC-derived Evidence: Serious hyperglycaemia with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 14.518 MAGIC-derived Evidence: Severe gastrointestinal events with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 14.519 MAGIC-derived Evidence: Severe gastrointestinal events with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 14.520 MAGIC-derived InterventionOnlyEvidence: All-cause mortality in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 14.521 MAGIC-derived InterventionOnlyEvidence: All-cause mortality in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 14.522 MAGIC-derived InterventionOnlyEvidence: Body weight in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 14.523 MAGIC-derived InterventionOnlyEvidence: Body weight in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 14.524 MAGIC-derived InterventionOnlyEvidence: Cardiovascular mortality in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 14.525 MAGIC-derived InterventionOnlyEvidence: Cardiovascular mortality in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 14.526 MAGIC-derived InterventionOnlyEvidence: Diabetic ketoacidosis in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 14.527 MAGIC-derived InterventionOnlyEvidence: End-stage kidney disease in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 14.528 MAGIC-derived InterventionOnlyEvidence: End-stage kidney disease in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 14.529 MAGIC-derived InterventionOnlyEvidence: Genital infection in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 14.530 MAGIC-derived InterventionOnlyEvidence: Health-related quality of life in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 14.531 MAGIC-derived InterventionOnlyEvidence: Health-related quality of life in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 14.532 MAGIC-derived InterventionOnlyEvidence: Heart failure in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 14.533 MAGIC-derived InterventionOnlyEvidence: Heart failure in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 14.534 MAGIC-derived InterventionOnlyEvidence: Nonfatal myocardial infarction in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 14.535 MAGIC-derived InterventionOnlyEvidence: Nonfatal myocardial infarction in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 14.536 MAGIC-derived InterventionOnlyEvidence: Nonfatal stroke in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 14.537 MAGIC-derived InterventionOnlyEvidence: Nonfatal stroke in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 14.538 MAGIC-derived InterventionOnlyEvidence: Serious hyperglycaemia in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 14.539 MAGIC-derived InterventionOnlyEvidence: Serious hyperglycaemia in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 14.540 MAGIC-derived InterventionOnlyEvidence: Severe gastrointestinal events in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 14.541 MAGIC-derived InterventionOnlyEvidence: Severe gastrointestinal events in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 14.542 Mean Change in Blood Urea Nitrogen (NCT03640312)
.... 14.543 Mean Change in Blood Urea Nitrogen at 12 weeks for Candesartan in NCT03640312
.... 14.544 Mean Change in Blood Urea Nitrogen at 12 weeks for QUARTET LDQT in NCT03640312
.... 14.545 Mean Change in Blood Urea Nitrogen at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 14.546 Mean Change in Serum Creatinine (NCT03640312)
.... 14.547 Mean Change in Serum Creatinine at 12 weeks for Candesartan in NCT03640312
.... 14.548 Mean Change in Serum Creatinine at 12 weeks for QUARTET LDQT in NCT03640312
.... 14.549 Mean Change in Serum Creatinine at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 14.550 Mean Change in Serum Potassium (NCT03640312)
.... 14.551 Mean Change in Serum Potassium at 12 weeks for Candesartan in NCT03640312
.... 14.552 Mean Change in Serum Potassium at 12 weeks for QUARTET LDQT in NCT03640312
.... 14.553 Mean Change in Serum Potassium at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 14.554 Mean Change in Serum Sodium (NCT03640312)
.... 14.555 Mean Change in Serum Sodium at 12 weeks for Candesartan in NCT03640312
.... 14.556 Mean Change in Serum Sodium at 12 weeks for QUARTET LDQT in NCT03640312
.... 14.557 Mean Change in Serum Sodium at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 14.558 Mean Diastolic Blood Pressure (NCT03640312)
.... 14.559 Mean Diastolic Blood Pressure at 6 weeks for Candesartan in NCT03640312
.... 14.560 Mean Diastolic Blood Pressure at 6 weeks for QUARTET LDQT in NCT03640312
.... 14.561 Mean Diastolic Blood Pressure at 6 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 14.562 Mean Systolic Blood Pressure (NCT03640312)
.... 14.563 Mean Systolic Blood Pressure at 6 weeks for Candesartan in NCT03640312
.... 14.564 Mean Systolic Blood Pressure at 6 weeks for QUARTET LDQT in NCT03640312
.... 14.565 Mean Systolic Blood Pressure at 6 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 14.566 Median Age of Parachute Intervention Group
.... 14.567 Medication Adherence (NCT03640312)
.... 14.568 Medication Adherence at 12 weeks
.... 14.569 Medication Adherence at 12 weeks for Candesartan in NCT03640312
.... 14.570 Medication Adherence at 12 weeks for QUARTET LDQT in NCT03640312
.... 14.571 Medication Adherence at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 14.572 MetaanalysisEligibilityCriteria: Mean difference in HbA1c effect of bariatric surgery in type 2 diabetes and elevated BMI in 2016 meta-analysis
.... 14.573 MetaanalysisOutcomeDefinition: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups at end of follow-up
.... 14.574 MetaanalysisStudyGroup: Effect Estimates for Mortality at 14 days from COVID19 Remdesivir vs. Placebo RCTs
.... 14.575 MetaanalysisStudyGroup: Study results included in Mean difference in HbA1c effect of bariatric surgery in 2016 meta-analysis
.... 14.576 Mortality at 14 days
.... 14.577 NCT03421379 Eligibility Criteria
.... 14.578 NCT03640312 Eligibility Criteria
.... 14.579 NetEffectContribution: Additional GI surgical procedure for Example for GIN 2022
.... 14.580 NetEffectContribution: All-cause mortality for Example for GIN 2022
.... 14.581 NetEffectContribution: New onset depression for Example for GIN 2022
.... 14.582 NetEffectContribution: Nonfatal myocardial infarction or stroke for Example for GIN 2022
.... 14.583 NetEffectContribution: Remission of diabetes for Example for GIN 2022
.... 14.584 NetEffectContribution: Treatment with opioids for Example for GIN 2022
.... 14.585 NetEffectContributionList: Bariatric Surgery Example for GIN 2022
.... 14.586 NetEffectContributions: Bariatric Surgery Example for GIN 2022
.... 14.587 NetEffectEstimate: Bariatric Surgery Example for GIN 2022
.... 14.588 NHANES LBDGLUSI Variable Definition Cohort Definition
.... 14.589 NHANES LBDGLUSI: Fasting Glucose (mmol/L)
.... 14.590 NHANES LBXGLU Variable Definition Cohort Definition
.... 14.591 NHANES LBXGLU: Fasting Glucose (mg/dL)
.... 14.592 NHANES Plasma Fasting Glucose (GLU_J) Data Dictionary
.... 14.593 NHANES SEQN Respondent Sequence Number
.... 14.594 NHANES WTSAF2YR Variable Definition Cohort Definition
.... 14.595 NHANES WTSAF2YR: Fasting Subsample 2 Year MEC Weight
.... 14.596 Norwegian Cohort Study Comparing Bariatric Surgery vs Medical Obesity Treatment for Long-term Medical Complications and Obesity-Related Comorbidities
.... 14.597 NT-proBNP Study Data Dictionary
.... 14.598 Number of Patients Requiring Step up Treatment (NCT03640312)
.... 14.599 Number of Patients Requiring Step up Treatment at 6 weeks for Candesartan in NCT03640312
.... 14.600 Number of Patients Requiring Step up Treatment at 6 weeks for QUARTET LDQT in NCT03640312
.... 14.601 Number of Patients Requiring Step up Treatment at 6 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 14.602 Organ support-free days
.... 14.603 Outcome Importance Rating 100 of All-cause mortality
.... 14.604 Outcome Importance Rating 30 of Nonfatal myocardial infarction or stroke
.... 14.605 Outcome Importance Rating 5 of New onset depression
.... 14.606 Outcome Importance Rating 5 of Remission of diabetes
.... 14.607 Outcome Importance Rating 5 of Treatment with opioids
.... 14.608 Outcome Importance Rating 8 of Additional GI surgical procedure
.... 14.609 Outcome Measure List for QUARTET USA Trial
.... 14.610 Outcome Measure Report for QUARTET USA Trial
.... 14.611 Outcome Measure Report: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)
.... 14.612 Outcome Measures Report for NCT03640312
.... 14.613 Outcome Variables List for PARACHUTE Trial
.... 14.614 Outcome: Death or Major Traumatic Injury 30 days after Impact
.... 14.615 Outcome: Death or Major Traumatic Injury on Impact
.... 14.616 Outcome: Injury Severity Score 30 days after Impact
.... 14.617 Outcome: Injury Severity Score on Impact
.... 14.618 OutcomeDefinition: Injury Severity Score on Impact
.... 14.619 OutcomeDefinition: All-cause mortality
.... 14.620 OutcomeDefinition: All-cause mortality
.... 14.621 OutcomeDefinition: American Diabetes Association composite triple end point for metabolic control
.... 14.622 OutcomeDefinition: Body weight
.... 14.623 OutcomeDefinition: Body weight
.... 14.624 OutcomeDefinition: Cardiovascular mortality
.... 14.625 OutcomeDefinition: Cardiovascular mortality
.... 14.626 OutcomeDefinition: Diabetes in remission
.... 14.627 OutcomeDefinition: Diabetic ketoacidosis
.... 14.628 OutcomeDefinition: End-stage kidney disease
.... 14.629 OutcomeDefinition: End-stage kidney disease
.... 14.630 OutcomeDefinition: Genital infection
.... 14.631 OutcomeDefinition: HbA1c at 12 months
.... 14.632 OutcomeDefinition: HbA1c at 24 months
.... 14.633 OutcomeDefinition: HbA1c at 36 months
.... 14.634 OutcomeDefinition: HbA1c at 6 months
.... 14.635 OutcomeDefinition: HbA1c at 60 months
.... 14.636 OutcomeDefinition: Health-related quality of life
.... 14.637 OutcomeDefinition: Health-related quality of life
.... 14.638 OutcomeDefinition: Heart failure
.... 14.639 OutcomeDefinition: Heart failure
.... 14.640 OutcomeDefinition: Mortality at 14 days
.... 14.641 OutcomeDefinition: New onset depression
.... 14.642 OutcomeDefinition: Nonfatal myocardial infarction
.... 14.643 OutcomeDefinition: Nonfatal myocardial infarction
.... 14.644 OutcomeDefinition: Nonfatal myocardial infarction or stroke
.... 14.645 OutcomeDefinition: Nonfatal stroke
.... 14.646 OutcomeDefinition: Nonfatal stroke
.... 14.647 OutcomeDefinition: Serious hyperglycaemia
.... 14.648 OutcomeDefinition: Serious hyperglycaemia
.... 14.649 OutcomeDefinition: Severe gastrointestinal events
.... 14.650 OutcomeDefinition: Severe gastrointestinal events
.... 14.651 OutcomeList: Clinical Outcomes for Effects of Bariatric Surgery
.... 14.652 OutcomeMeasureReport: GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 14.653 OutcomeVariable: American Diabetes Association composite triple end point for metabolic control at 5 years
.... 14.654 OutcomeVariable: HbA1c at 12 months
.... 14.655 OutcomeVariable: HbA1c at 24 months
.... 14.656 OutcomeVariable: HbA1c at 36 months
.... 14.657 OutcomeVariable: HbA1c at 6 months
.... 14.658 OutcomeVariable: HbA1c at 60 months
.... 14.659 OutcomeVariable: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups at end of follow-up
.... 14.660 OutcomeVariable: New onset depression
.... 14.661 OutcomeVariable: Nonfatal myocardial infarction or stroke
.... 14.662 OutcomeVariable: Remission of diabetes
.... 14.663 OutcomeVariablesList: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)
.... 14.664 OutcomeVariable_Additional_GI_surgical_procedure
.... 14.665 OutcomeVariable_All_cause_mortality
.... 14.666 OutcomeVariable_Treatment_with_opioids
.... 14.667 PARACHUTE Trial baseline characteristics
.... 14.668 PARACHUTE Trial non participants
.... 14.669 PARACHUTE trial participant flow report
.... 14.670 PARACHUTE Trial Participants
.... 14.671 PARACHUTE Trial Participants assigned an empty backpack
.... 14.672 PARACHUTE trial participants assigned parachute
.... 14.673 PARACHUTE Trial Participants available for randomization
.... 14.674 PARACHUTE Trial Participants deemed unsuitable by investigator
.... 14.675 PARACHUTE Trial Participants randomized into groups
.... 14.676 PARACHUTE Trial Participants randomized into groups for screened group
.... 14.677 PARACHUTE Trial Participants randomized into groups with comparator
.... 14.678 PARACHUTE Trial Participants randomized into groups with intervention
.... 14.679 PARACHUTE Trial Participants that completed 30 day follow up
.... 14.680 PARACHUTE Trial Participants that completed 30 day follow up with comparator
.... 14.681 PARACHUTE Trial Participants that completed 30 day follow up with intervention
.... 14.682 PARACHUTE Trial Participants that completed jump and 5 minute follow-up
.... 14.683 PARACHUTE Trial Participants that completed jump and 5 minute follow-up with comparator
.... 14.684 PARACHUTE Trial Participants that completed jump and 5 minute follow-up with intervention
.... 14.685 PARACHUTE Trial Participants that declined randomization
.... 14.686 PARACHUTE Trial Participants with no contact at 30 days
.... 14.687 PARACHUTE Trial Participants with no contact at 30 days with comparator
.... 14.688 PARACHUTE Trial Participants with no contact at 30 days with intervention
.... 14.689 PARACHUTE Trial Results
.... 14.690 Parachute use to prevent death and major trauma when jumping from aircraft: randomized controlled trial.
.... 14.691 Parachute vs Empty Backpack in PARACHUTE Trial
.... 14.692 Participant Flow Report for NCT03640312
.... 14.693 Participant Flow Report for QUARTET USA Trial
.... 14.694 Participant Flow Variables List for PARACHUTE Trial
.... 14.695 ParticipantFlow: 2018 Norwegian Cohort Included in Analysis
.... 14.696 ParticipantFlow: 2018 Norwegian Cohort Medical Group Included in Analysis
.... 14.697 ParticipantFlow: 2018 Norwegian Cohort Surgical Group Included in Analysis
.... 14.698 ParticipantFlowEvidence: 2018 Norwegian Cohort Excluded from Analysis
.... 14.699 ParticipantFlowMeasure: Dropout due to stopping intervention
.... 14.700 ParticipantFlowMeasure: Exclusion from analysis
.... 14.701 ParticipantFlowMeasure: Inclusion in analysis
.... 14.702 Participants Excluded from PARACHUTE Study
.... 14.703 Participants_in_Anticoagulation_for_COVID_19_Combined_ATTACC_ACTIV_4a_and_REMAP_CAP_RCT_hospitalized_not_critically_ill
.... 14.704 Patients_who_are_hospitalized_for_COVID_19_and_who_are_not_critically_ill
.... 14.705 PD: Time to Maximal Concentration (Tmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM (NCT03421379)
.... 14.706 Percentage of Participants Achieving Treatment Success During Controlled Insulin-Induced Hypoglycemia (NCT03421379)
.... 14.707 Percentage of Participants With Potentially Related Adverse Events (NCT03640312)
.... 14.708 Percentage of Participants With Potentially Related Adverse Events at 12 weeks for Candesartan in NCT03640312
.... 14.709 Percentage of Participants With Potentially Related Adverse Events at 12 weeks for QUARTET LDQT in NCT03640312
.... 14.710 Percentage of Participants With Potentially Related Adverse Events at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 14.711 Percentage of Participants With Serious Adverse Events (SAEs) (NCT03640312)
.... 14.712 Percentage of Participants With Serious Adverse Events (SAEs) at 12 weeks for Candesartan in NCT03640312
.... 14.713 Percentage of Participants With Serious Adverse Events (SAEs) at 12 weeks for QUARTET LDQT in NCT03640312
.... 14.714 Percentage of Participants With Serious Adverse Events (SAEs) at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 14.715 Pharmacodynamics (PD): Change From Baseline in Maximal Blood Glucose (BGmax) of Glucagon Nasal Powder and Glucagon Hydrochloride Intramuscular (IM) (NCT03421379)
.... 14.716 Pharmacokinetics (PK): Change From Baseline in Area Under the Concentration Versus Time Curve From Zero to Time t (AUC [0-tLast]) of Glucagon Nasal Powder and Glucagon Hydrochloride IM (NCT03421379)
.... 14.717 PK: Change From Baseline in Maximal Concentration (Cmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM (NCT03421379)
.... 14.718 PK: Change From Baseline in Tmax of Glucagon Nasal Powder and Glucagon Hydrochloride IM (NCT03421379)
.... 14.719 Placebo
.... 14.720 PlanDefinition for Recommendation: ADA Obesity Management Recommendation 8.16
.... 14.721 PlanDefinition for Recommendation: ADA Obesity Management Recommendation 8.17
.... 14.722 PreprintCitation: Nigella Sativa for COVID-19 OSF Preprint
.... 14.723 Proportion of Patients With Adverse Event Free Hypertension Control (NCT03640312)
.... 14.724 Proportion of Patients With Adverse Event Free Hypertension Control at 12 weeks for Candesartan in NCT03640312
.... 14.725 Proportion of Patients With Adverse Event Free Hypertension Control at 12 weeks for QUARTET LDQT in NCT03640312
.... 14.726 Proportion of Patients With Adverse Event Free Hypertension Control at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 14.727 Proportion of Patients With Hypertension Control (NCT03640312)
.... 14.728 Proportion of Patients With Hypertension Control at 6 and 12 weeks - 12 weeks at (NCT03640312)
.... 14.729 Proportion of Patients With Hypertension Control at 6 and 12 weeks - 12 weeks for Candesartan in NCT03640312
.... 14.730 Proportion of Patients With Hypertension Control at 6 and 12 weeks - 12 weeks for QUARTET LDQT in NCT03640312
.... 14.731 Proportion of Patients With Hypertension Control at 6 and 12 weeks - 6 weeks at (NCT03640312)
.... 14.732 Proportion of Patients With Hypertension Control at 6 and 12 weeks - 6 weeks for Candesartan in NCT03640312
.... 14.733 Proportion of Patients With Hypertension Control at 6 and 12 weeks - 6 weeks for QUARTET LDQT in NCT03640312
.... 14.734 Proportion of Patients With Hypertension Control at 6 and 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 14.735 Quadpill once daily
.... 14.736 QUARTET USA Trial Control Group
.... 14.737 QUARTET USA Trial Quadpill group
.... 14.738 randomized into groups for PARACHUTE Trial
.... 14.739 Rate of Adverse Events of Special Interest (NCT03640312)
.... 14.740 Rate of Adverse Events of Special Interest at 12 weeks for Candesartan in NCT03640312
.... 14.741 Rate of Adverse Events of Special Interest at 12 weeks for QUARTET LDQT in NCT03640312
.... 14.742 Rate of Adverse Events of Special Interest at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 14.743 Rate of Death or Major Traumatic Injury on Impact with comparator
.... 14.744 Rate of Death or Major Traumatic Injury on Impact with intervention
.... 14.745 Reasons for exclusion from QUARTET USA Trial
.... 14.746 Recommendation Eligibility Criteria for Bariatric Surgery (ADA Recommendation 8.17)
.... 14.747 Recommendation Justification Code System
.... 14.748 Recommendation Rating: ADA Obesity Management Recommendation 8.16
.... 14.749 Recommendation: ADA Obesity Management Recommendation 8.16
.... 14.750 Recommendation: ADA Obesity Management Recommendation 8.16-adapted
.... 14.751 Recommendation: ADA Obesity Management Recommendation 8.17
.... 14.752 RecommendationEligibilityCriteria: Eligibility Criteria for Bariatric Surgery (ADA Recommendation 8.16)
.... 14.753 Remdesivir
.... 14.754 Remdesivir IV 200 mg once then 100 mg once daily for 9 days
.... 14.755 Results Section for NCT03421379
.... 14.756 Results Section for NCT03640312
.... 14.757 Risk of Bias Assessment of Critically appraised summary of primary outcome of multi-platform RCT of anticoagulation for non-critically ill patients with COVID-19
.... 14.758 Risk of Bias Assessment of PARACHUTE trial
.... 14.759 Risk Of Bias Type Value Set
.... 14.760 Screened Group PARACHUTE Trial
.... 14.761 Search Strategy for NMA_Diabetes
.... 14.762 SearchResults: PubMed search for Wonder Woman
.... 14.763 SearchStrategy: PubMed and Embase search for van Veldhuisen 2022 systematic review
.... 14.764 SearchStrategy: PubMed search for Wonder Woman
.... 14.765 Sex
.... 14.766 Sex with comparator
.... 14.767 Sex with intervention
.... 14.768 SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 14.769 SoaPlanDefinition: Follow-up assessment 3 months after study start
.... 14.770 SoftwareCitation: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter
.... 14.771 Spanish or English Value Set
.... 14.772 Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 14.773 StudyCitation: 2022 Systematic Review of bariatric surgery mortality effect 35243488
.... 14.774 StudyEligibilityCriteria: Eligibility Criteria for DIBASY Trial
.... 14.775 StudyEligibilityCriteria: Obese patients ≥ 18 years old
.... 14.776 StudyEligibilityCriteria: Type 2 diabetes and elevated BMI in 2016 meta-analysis
.... 14.777 StudyEligibilityCriteria_Eligibility_Criteria_for_Bariatric_Surgery_Randomized_Trial_Diabetes_Surgery_Study
.... 14.778 StudyGroup: Diabetes Surgery Study Trial Enrollment Group
.... 14.779 StudyGroup: Severely Obese Adults 2018 Norwegian Cohort
.... 14.780 StudyGroup_DIBASY_Trial_Enrollment_Group
.... 14.781 Summary of Findings - QUARTET USA Trial
.... 14.782 SummaryOfFindings: Bariatric Surgery Summary of Findings Example for GIN 2022
.... 14.783 SummaryOfFindings: GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 14.784 SummaryOfFindings: SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 14.785 SummaryOfNetEffect: Bariatric Surgery Summary of Net Effect Contributions Example for GIN 2022
.... 14.786 SystematicReviewEligibilityCriteria: ADT and Docetaxel vs. ADT alone for metastatic hormone-naive prostate cancer
.... 14.787 SystematicReviewExcludedStudies: ADT and Docetaxel vs. ADT alone for metastatic hormone-naive prostate cancer
.... 14.788 SystematicReviewIncludedStudies: ADT and Docetaxel vs. ADT alone for metastatic hormone-naive prostate cancer
.... 14.789 Systolic blood pressure at 12 weeks
.... 14.790 Time to integration of results in a recommendation
.... 14.791 VariableDefinition: Comparator
.... 14.792 VariableDefinition: Condition(s)
.... 14.793 VariableDefinition: Date of birth
.... 14.794 VariableDefinition: Date of measurement
.... 14.795 VariableDefinition: Gender
.... 14.796 VariableDefinition: NTproBNP
.... 14.797 VariableDefinition: Unit
.... 14.798 Velocity
.... 14.799 Velocity comparing intervention vs. comparator
.... 14.800 Velocity for enrolled group
.... 14.801 Velocity for non participant group
.... 14.802 Velocity with comparator
.... 14.803 Velocity with intervention
.... 14.804 WebPageCitation: A HEvKA Update Summary
.... 14.805 Weight
.... 14.806 Weight with comparator
.... 14.807 Weight with intervention